Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | METAP1 | P53582 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381780 | 0.85 | MAPT (0.49) | MAPTKDM4ELMNAMETAP2METAP1 | |
| SCHEMBL3011815 | 0.84 | MAPT (0.48) | MAPTKDM4ELMNAMETAP2METAP1 | |
| SCHEMBL721177 | 0.81 | MAPT (0.48) | MAPTKDM4ELMNAMETAP2METAP1 | |
| Butane SCHEMBL3022746 | 0.80 | MAPT (0.48) | MAPTKDM4ELMNAMETAP2METAP1 | |
| SCHEMBL4381777 | 0.78 | LMNA (0.50) | MAPTKDM4ELMNAMETAP2METAP1 | |
| SCHEMBL3011819 | 0.77 | MAPT (0.54) | MAPTKDM4ELMNAHDAC6ALDH1A1 | |
| SCHEMBL24179773 | 0.75 | LMNA (0.55) | MAPTKDM4ELMNAMETAP2METAP1 | |
| SCHEMBL28128326 | 0.75 | MAPT (0.51) | MAPTKDM4ELMNAMETAP2METAP1 | |
| SCHEMBL13212807 | 0.75 | MAPT (0.55) | MAPTKDM4ELMNAHDAC6ALDH1A1 | |
| SCHEMBL8664206 | 0.74 | KDM4E (0.53) | MAPTKDM4ELMNAMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522394-B1 | Substituted phosphonates and their use decreasing amyloid aggregates | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-8513219-B2 | Substituted phosphonates and their use in decreasing amyloid aggregates | QUEEN MARY & WESTFIELD COLLEGE, UNIVERSITY OF LONDON (GB) | 2013-08-20 | — | — | US | disclosed |
| EP-2522394-A2 | Substituted phosphonates and their use decreasing amyloid aggregates | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2012-11-14 | — | — | EP | disclosed |
| US-20100204183-A1 | Substituted Phosphonates and Their Use In Decreasing Amyloid Aggregates | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2010-08-12 | — | — | US | disclosed |
| EP-2152368-A1 | SUBSTITUTED PHOSPHONATES AND THEIR USE IN DECREASING AMYLOID AGGREGATES | Queen Mary and Westfield College (GB) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008135743-A1 | SUBSTITUTED PHOSPHONATES AND THEIR USE IN DECREASING AMYLOID AGGREGATES | QUEEN MARY AND WESTFIELD COLLEGE (GB) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204183-A1 | Substituted Phosphonates and Their Use In Decreasing Amyloid Aggregates | PSEN2, PSEN1, APP | MAPT 4/4885KDM4E 4149/4885LMNA 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.